We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Securities and Exchange Commission (SEC) has worked out a settlement with Vaso Active Pharmaceuticals and its chief executive over alleged misrepresentations made by the company.